Shannon N. Westin, MD, MPH, Discussed the Wee1 Inhibitor Adavosertib for PARPi-Resistant Ovarian Cancer

CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Shannon N. Westin, MD, MPH, of the University of Texas MD Anderson Cancer Center, about efficacy with the Wee1 inhibitor adavosertib observed in the phase 2 EFFORT trial (NCT03579316). In a patient population with a median of 4 prior lines of therapy, the agent showed a 23% overall response rate. Toxicity led to dose interruptions in most patients, but grade 3/4 adverse effects were considered to be manageable.

Here, Westin discusses how these data may be of use to the multidisciplinary team.


Similar to what we’ve seen with other combination strategies, it really is important to engage the patient, your pharmacist, and your nursing staff to make sure that everybody’s aware of the potential [adverse] effects and set expectations to really make sure patients know we may start on 1 dose, but there may be a need to hold and to reduce as needed to make this tolerable for you. I think that would be the major thing.

Now as far as where this is going. Scientifically, this is very exciting that clinically we’re seeing the benefit we need, but it’s not quite ready for primetime. We need to do a little bit more study before it’s going to be [in] the hands of clinicians out in practice.


Westin SN, Coleman RL, Fellman BM, et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J Clin Oncol. 2021;39(suppl 15):5505. doi:10.1200/JCO.2021.39.15_suppl.5505